EYPT Live signals | Maximize Profits with Getagraph.com

SELL 157494 min ago

@ $29.50

Issued: 14 Feb 2024 @ 15:25

Return: -63.69%

Previous signal: Feb 14 - 13:36

Previous signal: Buy

Return: 0.61 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom...

Stats
Today's Volume	1.06M
Average Volume	1.14M
Market Cap	557.82M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $-0.420 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.92
ATR14	$0.0190 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-25	Elston George	Buy	7 500	Common Stock
2024-05-25	Elston George	Sell	3 627	Common Stock
2024-05-25	Elston George	Sell	7 500	Restricted Stock Units
2024-05-14	Guyer David R	Sell	6 525	Stock Option (Right to Buy)
2024-05-14	Guyer David R	Buy	3 250	Common Stock

INSIDER POWER
62.62
Last 98 transactions
Buy: 1 900 812 \| Sell: 475 595

Volume Correlation

Long: -0.52 (weak negative)

Short: 0.28 (neutral)

Signal:(54.723) Neutral

EyePoint Pharmaceuticals Correlation

10 Most Positive Correlations
WDAY	0.904
WRAP	0.894
GTEC	0.884
CTSH	0.878
DOMO	0.87
JBHT	0.867
HURN	0.864
ZS	0.861
APLS	0.86
DRUG	0.859

10 Most Negative Correlations
TNDM	-0.893
VIRT	-0.886
PUI	-0.884
MMLP	-0.881
TIGO	-0.86
HCM	-0.854
RILYG	-0.854
BNTC	-0.854
BILI	-0.854
VERU	-0.852

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

EyePoint Pharmaceuticals Correlation - Currency/Commodity

0.72
( moderate )

0.00
( neutral )

0.62
( weak )

-0.57
( weak negative )

EyePoint Pharmaceuticals Financials

Annual	2023
Revenue:	$46.02M
Gross Profit:	$41.39M (89.93 %)
EPS:	$-1.820

FY	2023
Revenue:	$46.02M
Gross Profit:	$41.39M (89.93 %)
EPS:	$-1.820

FY	2022
Revenue:	$41.40M
Gross Profit:	$33.08M (79.89 %)
EPS:	$-3.34

FY	2021
Revenue:	$36.94M
Gross Profit:	$28.76M (77.86 %)
EPS:	$-4.55

Financial Reports:

No articles found.

EyePoint Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.